Zelalem Temesgen

4.0k total citations
117 papers, 1.9k citations indexed

About

Zelalem Temesgen is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Zelalem Temesgen has authored 117 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Infectious Diseases, 36 papers in Epidemiology and 34 papers in Virology. Recurrent topics in Zelalem Temesgen's work include HIV/AIDS drug development and treatment (35 papers), HIV Research and Treatment (34 papers) and HIV/AIDS Research and Interventions (24 papers). Zelalem Temesgen is often cited by papers focused on HIV/AIDS drug development and treatment (35 papers), HIV Research and Treatment (34 papers) and HIV/AIDS Research and Interventions (24 papers). Zelalem Temesgen collaborates with scholars based in United States, Italy and Ethiopia. Zelalem Temesgen's co-authors include Sandro Vento, Francesca Cainelli, Elie F. Berbari, John D. Zeuli, Alan J. Wright, Mary J. Kasten, Douglas R. Toal, Franklin R. Cockerill, Christina G. Rivera and Jason N. Barreto and has published in prestigious journals such as The Lancet, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Zelalem Temesgen

113 papers receiving 1.8k citations

Peers

Countries citing papers authored by Zelalem Temesgen

Since Specialization

Citations

This map shows the geographic impact of Zelalem Temesgen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zelalem Temesgen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zelalem Temesgen more than expected).

Fields of papers citing papers by Zelalem Temesgen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zelalem Temesgen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zelalem Temesgen. The network helps show where Zelalem Temesgen may publish in the future.

Co-authorship network of co-authors of Zelalem Temesgen

This figure shows the co-authorship network connecting the top 25 collaborators of Zelalem Temesgen. A scholar is included among the top collaborators of Zelalem Temesgen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zelalem Temesgen. Zelalem Temesgen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	HIV Pre-Exposure Prophylaxis: New and Upcoming Drugs to Address the HIV Epidemic 2023 ·Drugs ·Christina G. Rivera, John D. Zeuli, Bradley L. Smith, (unknown), Ramona Bhatia, (unknown), Zelalem Temesgen	8
2	Prevention of the Vertical Transmission of HIV; A Recap of the Journey so Far 2023 ·Viruses ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Supriya Behl, Sohan Punia, Elizabeth Ann L. Enninga, Erica L. Johnson, Zelalem Temesgen, Regan N. Theiler, Clive M. Gray, Rana Chakraborty	15
3	C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial 2022 ·Thorax ·Zelalem Temesgen, Colleen F. Kelley, Frank Cerasoli, Adrian Kilcoyne, Dale Chappell, Cameron Durrant, Omar Abdihamid, (unknown), Victoria M. Catterson, Christopher Polk, Andrew D. Badley, Vincent C. Marconi	8
4	Clostridioides difficile infection in solid organ and hematopoietic stem cell transplant recipients: A prospective multinational study 2021 ·Transplant Infectious Disease ·Emily A. Blumberg, Gary Collins, Jo‐Anne H. Young, M. Hong Nguyen, David Michonneau, Zelalem Temesgen, Julia Origüen, Laura Barcán, (unknown), Waldo Belloso, Julien Gras, Giulio Maria Corbelli, James D. Neaton, Jens Lundgren, David R. Snydman, Jean‐Michel Molina, (unknown)	4
5	Point-of-care program in HIV, tuberculosis, and associated conditions: A virtual global technical assistance platform to strengthen HIV and tuberculosis workforce capacity 2021 ·Journal of Clinical Tuberculosis and Other Mycobacterial Diseases ·(unknown), (unknown), Stacey A. Rizza, Maryam Mahmood, Roger Bedimo, Ramona Bhatia, (unknown), (unknown), Zelalem Temesgen	1
6	Disseminated Nocardia in an Immunocompetent Host 2021 ·Mayo Clinic Proceedings ·(unknown), (unknown), Zelalem Temesgen	6
7	School factors against co-curricular participation of students with mobility problem 2018 ·SHILAP Revista de lepidopterología ·Zelalem Temesgen	1
8	School Challenges of Students with Visual Disabilities. 2018 ·International Journal of Special Education (IJSE) ·Zelalem Temesgen	10
9	Tuberculosis control, and the where and why of artificial intelligence 2017 ·ERJ Open Research ·Riddhi Doshi, Dennis Falzon, Bruce Thomas, Zelalem Temesgen, (unknown), Giovanni Battista Migliori, Mario Raviǵlione	20
10	Babesia microti infection and hemophagocytic lymphohistiocytosis in an immunocompetent patient 2017 ·International Journal of Infectious Diseases ·(unknown), (unknown), (unknown), Zelalem Temesgen, Thomas J. Beckman	5
11	Perspectives in therapy for hepatitis C 2008 ·Expert Opinion on Investigational Drugs ·Sandro Vento, Francesca Cainelli, Zelalem Temesgen	3
12	Etravirine 2008 ·Drugs of today ·Bettina M. Knoll, Sandro Vento, Zelalem Temesgen	8
13	Current status of HIV infection: a review for non‐HIV‐treating physicians 2007 ·International Journal of Dermatology ·Bettina M. Knoll, Britta Lassmann, Zelalem Temesgen	21
14	Drug evaluation: bevirimat--HIV Gag protein and viral maturation inhibitor. 2006 ·PubMed ·Zelalem Temesgen, Judith Feinberg	8
15	Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults 2006 ·The Lancet Infectious Diseases ·Zelalem Temesgen, Francesca Cainelli, Eric M. Poeschla, (unknown), Sandro Vento	19
16	SARS: Epidemiology, Clinical Presentation, Management, and Infection Control Measures 2003 ·Mayo Clinic Proceedings ·Priya Sampathkumar, Zelalem Temesgen, Thomas F. Smith, Rodney L. Thompson	59
17	Interleukin-2 liposomes for primary immune deficiency using the aerosol route 2002 ·International Immunopharmacology ·Rosa Ten, Peter M. Anderson, Nizar N. Zein, Zelalem Temesgen, (unknown), Jason Weiss	36
18	Overview of HIV infection 1999 ·Annals of Allergy Asthma & Immunology ·Zelalem Temesgen	12
19	Central Nervous System Histoplasmosis Mimicking a Brain Tumor: Difficulties in Diagnosis and Treatment 1999 ·Mayo Clinic Proceedings ·Christopher J. Klein, Robert P. Dinapoli, Zelalem Temesgen, Fredric B. Meyer	31
20	A COMPARATIVE STATISTICAL STUDY OF MAJOR DISCIPLINE CHOICE OF SCIENCE FRESHMAN STUDENTS 1996 ·Zelalem Temesgen	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact